Related Experiment Videos
Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction
S Francavilla1, G Properzi, C Bellini
1Department of Internal Medicine, University of L'Aquila, Rome, Italy.
The Journal of Urology
|October 23, 1997
Summary
Plasma endothelin-1 levels are elevated in men with erectile dysfunction, particularly in those with diabetes. Intracavernous prostaglandin E1 did not alter endothelin-1 levels in the cavernous body blood.
Area of Science:
- Urology
- Endocrinology
- Vascular Biology
Background:
- Erectile dysfunction (ED) is a common condition with multifactorial causes.
- Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in vascular pathologies.
Purpose of the Study:
- To investigate plasma ET-1 concentrations in men with ED, comparing diabetic and nondiabetic individuals.
- To assess ET-1 variations in cavernous body blood following prostaglandin E1 (PGE1) induced erection.
Main Methods:
- Plasma ET-1 levels were measured in the cubital vein of 20 men with ED (10 diabetic, 10 nondiabetic) and controls.
- Cavernous body blood ET-1 was evaluated pre- and post-PGE1 injection (10 mcg).
- Patients with severe vasculogenic ED were excluded.
Main Results:
- Basal plasma ET-1 was significantly higher in both diabetic and nondiabetic ED patients compared to controls.
- Diabetic ED patients exhibited higher plasma ET-1 than nondiabetic ED patients.
- No significant changes or differences in cavernous ET-1 were observed post-PGE1 injection, correlating closely with peripheral levels.
Conclusions:
- Elevated plasma ET-1 may contribute to ED pathogenesis, especially in diabetic men.
- PGE1-induced vasodilation does not appear to acutely alter ET-1 concentrations within the penile vasculature in this cohort.